Navigation Links
HUYA Bioscience Int'l Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
Date:3/3/2008

Progress validates HUYA's innovative U.S./China pharmaceutical

co-development model

SAN FRANCISCO, March 3 /PRNewswire/ -- IBC Conference -- HUYA Bioscience International (HUYA), the leader in U.S./China pharmaceutical co-development, today announced the completion of three Phase I clinical trial protocols in China of a promising anti-arrhythmic compound, HBI-3000 (Sulcardine sulphate). The data from the trials support a desirable safety profile at dose levels displaying indications of pharmacologic activity. HBI-3000 is being developed as a potential treatment for both atrial and ventricular arrhythmias.

Anti-arrhythmic drugs are used today to treat patients with atrial fibrillation (AF), a serious condition that afflicts 5.6 million Americans. Anti-arrhythmic agents have also been used for the treatment of ventricular arrhythmias, although most have failed to demonstrate a survival advantage, and in some cases carry significant safety risk.

The main concern with anti-arrhythmic drugs is an increased risk of sudden death (Torsade de Pointes) in patients with underlying organic heart disease such as coronary artery disease, prior history of myocardial infarction and heart failure. A large subset of individuals with atrial and ventricular arrhythmias suffers from these conditions, precluding treatment with most existing anti-arrhythmic drugs. Development of safe anti-arrhythmic agents for use in these patients is needed. Pre-clinical data developed by HUYA and its Chinese partner, along with the Chinese clinical trial data suggest that HBI-3000 may have safety advantages over other anti-AF agents and exhibits broad spectrum ion channel inhibition without pro-arrhythmic activity that suggests it may also be safer to use in treatment of ventricular arrhythmias.

According to Mireille Gingras, Ph.D., CEO of HUYA, "the progress on this exciting new compound validates the efficiency and effectiveness of our co-development model with our Chinese partners. With HBI-3000, for example, we will have the opportunity to collaborate with our Chinese partners on their Phase II trials, which will be valuable in the U.S. development process. We leverage the knowledge and experience of both teams -- in addition to existing Phase I data from China -- to streamline and optimize that process in both countries. Our model sets a new standard for integrated, China/U.S. pharmaceutical co-development."

HUYA's innovative co-development model

HUYA was one of the first companies to recognize the potential of China as a source for novel pre-clinical and clinical stage compounds and pioneered an innovative co-development model. HUYA partners with Chinese research institutions and pharmaceutical companies to leverage and extend their research efforts, accelerate development, and provide a bridge into the U.S. development process and the biopharma market.

This model contrasts with that of large pharmaceutical companies whose approach is to start their own research facilities in China hoping to tap its large biotech talent pool, or that of smaller competitors with "one-off" single compound strategies. With three strategic offices in China, the broadest Chinese compound portfolio, and more exclusive agreements with premier Chinese biotech centers than any other company, HUYA is uniquely positioned to identify and license novel Chinese compounds. Moreover, the strength of its relationships with its Chinese partners ensures a continuous source of these compounds for the future.

One of the key differentiators of HUYA's approach is the assembly of a world-class team of scientific and clinical advisors for each promising new compound, such as HBI-3000. This team collaborates with its Chinese partners and is then able to leverage and extend these efforts as the compounds enter the development process in the U.S, speeding the process and mitigating risk.

The U.S. advisors (announced in a separate release) for HBI-3000 comprise a world class team of scientists and clinicians including Benedict Lucchesi, Ph.D. MD, Peter R. Kowey, M.D., Dennis Roy, M.D., Jefferson L. Anderson, M.D., Eric J. Topol, M.D., and Stanley Nattel, M.D.

About HUYA

HUYA is the leader in U.S./China pharmaceutical co-development, formed to meet the global need for new, untapped sources of pre-clinical and clinical stage compounds. HUYA identifies the most promising new compounds in China and partners with Chinese research institutions to leverage and extend their research efforts, accelerate development, and provide a bridge into the U.S. development process and the biopharma market. With three strategic offices in China, the broadest Chinese compound portfolio, and more exclusive agreements with premier Chinese biotech centers than any other company, HUYA has pioneered the most innovative and productive approach for pharmaceutical co-development between the U.S and China. Further information about the company is available at http://www.huyabio.com.

Contact:

USA:

Jan Tuttleman, Ph.D.

Vice President, Marketing

HUYA Bioscience International

(858) 798-8800

jtuttleman@huyabio.com

China:

Wen Chen, M.S., MBA

EVP China Operation and Chief Representative

HUYA Bioscience International

86 (21) 51323312

wchen@huyabio.com

Media Contacts:

Amy Berry

(415) 793-2258

amyeberry@comcast.net

Juliet Travis

(510) 452-3771

juliet@travispr.com


'/>"/>
SOURCE HUYA Bioscience International
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. On Second Anniversary, Compendia Bioscience Announces Significant Revenue Growth, Completion of Product Milestone and Expansion of Pharma Customer Commitments
2. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
3. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
4. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
5. CeloNova BioSciences Introduces a New Class of Coronary Stent: The CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F
6. CeloNova BioSciences Announces Positive Results from European Study of Embozene(TM) Microspheres for Treatment of Uterine Fibroids
7. Epiphany Biosciences Reports Initiation of Phase 2 Study of Valomaciclovir for the Treatment of Acute Infectious Mononucleosis
8. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
9. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
10. Epiphany Biosciences Reports Initiation and Enrollment in Valomaciclovir Study for Shingles
11. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... Research and Markets has announced the addition of the "Global ... ... artificial pancreas devices system market to grow at a CAGR of ... System Market 2016-2020, has been prepared based on an in-depth market ... landscape and its growth prospects over the coming years. The report ...
(Date:1/17/2017)... Jan. 17, 2017 The Global Nebulizers Market ... 8.2% over the next decade to reach approximately $1698.68 ... the market is witnessing include rapidly growing demand in ... advancements in nebulizer products and online marketing strategies by ... market is categorized into pneumatic nebulizers, ultrasonic nebulizers and ...
(Date:1/17/2017)...  Edwards Lifesciences Corporation (NYSE: EW ), ... disease and critical care monitoring, plans to announce its ... after the market closes on Wednesday, February 1, 2017, ... ET that day to discuss those results. ... or (201) 689-8037.  For 72 hours following the call, ...
Breaking Medicine Technology:
(Date:1/17/2017)... ... January 17, 2017 , ... Metro Development Group has ... high speed technology into the fabric of an entire community. A highlight of ... and wellness in a yet-to-be-named, health focused campus. Leading this initiative in partnership ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... education for EMS and firefighting professionals, has released four new continuing education courses ... courses are taught live in an online classroom and meet the requirements of ...
(Date:1/17/2017)... ... ... A prescription medication bottle, pocket knife, luggage and a solar-powered aluminum casting ... Challenge , the Cradle to Cradle Products Innovation Institute has announced. , ... run through early 2018. The challenges are presented by the Institute in partnership with ...
(Date:1/17/2017)... , ... January 17, 2017 , ... ... financial planning assistance to families and business professionals throughout central Colorado, is joining ... homeless families. , The Aurora Warms The Night organization is committed to breaking ...
(Date:1/17/2017)... ... January 17, 2017 , ... Seceon , ... threats in real-time, today announced a strategic partnership with TechLab Security, ... other Seceon partners, TechLab Security has become a strategic partner and a value ...
Breaking Medicine News(10 mins):